Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy

S. Barel, B. Yagen, V. Schurig, S. Soback, F. Pisani, E. Perucca, M. Bialer

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objective: To investigate the pharmacokinetics of the four stereoisomers of valnoctamide, a mild tranquilizer endowed with anticonvulsant properties. Methods: Racemic valnoctamide, 400 mg, was administered orally to seven healthy subjects and to six patients with epilepsy stabilized with long-term carbamazepine therapy. In the patients with epilepsy, valnoctamide kinetics was also reassessed after 8-day oral dosing at a dosage of 600 mg daily. Plasma samples were assayed by gas chromatography-mass spectrometry with use of a capillary column coated with chiral stationary phase that enabled baseline resolution of the four stereoisomers, designated hereafter as A, B, C, and D (where A and C, together with B and D, represent enantiomeric pairs). Results: In healthy subjects, stereoisomers A, C, and D showed similar kinetics, with an apparent oral clearance (CL/F) of about 4 1/4 L/hr, a half-life (t( 1/4 )) of about 10 hours, and an apparent volume of distribution (V(SS)/F) of about 65 L. However, stereoisomer B showed a much higher clearance (8.7 ± 0.9 L/hr) and a shorter t( 1/4 ) (5.8 hours). For all stereoisomers, CL/F values in patients with epilepsy were about tenfold higher than those found in healthy subjects. Compared with healthy subjects, patients with epilepsy also showed shorter t( 1/4 ) values and higher V(SS)/F values for each of the stereoisomers. After 7-day dosing, CL/F values at steady state were lower than those determined in the same patients after a single dose. Conclusions: Valnoctamide exhibits enantioselectivity and diastereoselectivity, an observation that may have important practical implications if pharmacodynamic differences between stereoisomers are also found. The observed pharmacokinetic differences between healthy subjects and patients with epilepsy are likely to be related to induction of metabolism of valnoctamide stereoisomers by carbamazepine.

Original languageEnglish
Pages (from-to)442-449
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume61
Issue number4
Publication statusPublished - 1997

Fingerprint

Stereoisomerism
Epilepsy
Healthy Volunteers
Pharmacokinetics
Carbamazepine
Dilatation and Curettage
valnoctamide
Anticonvulsants
Gas Chromatography-Mass Spectrometry
Half-Life
Observation

ASJC Scopus subject areas

  • Pharmacology

Cite this

Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. / Barel, S.; Yagen, B.; Schurig, V.; Soback, S.; Pisani, F.; Perucca, E.; Bialer, M.

In: Clinical Pharmacology and Therapeutics, Vol. 61, No. 4, 1997, p. 442-449.

Research output: Contribution to journalArticle

Barel, S, Yagen, B, Schurig, V, Soback, S, Pisani, F, Perucca, E & Bialer, M 1997, 'Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy', Clinical Pharmacology and Therapeutics, vol. 61, no. 4, pp. 442-449.
Barel, S. ; Yagen, B. ; Schurig, V. ; Soback, S. ; Pisani, F. ; Perucca, E. ; Bialer, M. / Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. In: Clinical Pharmacology and Therapeutics. 1997 ; Vol. 61, No. 4. pp. 442-449.
@article{0f919d4a4f6a48efb995934deb097699,
title = "Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy",
abstract = "Objective: To investigate the pharmacokinetics of the four stereoisomers of valnoctamide, a mild tranquilizer endowed with anticonvulsant properties. Methods: Racemic valnoctamide, 400 mg, was administered orally to seven healthy subjects and to six patients with epilepsy stabilized with long-term carbamazepine therapy. In the patients with epilepsy, valnoctamide kinetics was also reassessed after 8-day oral dosing at a dosage of 600 mg daily. Plasma samples were assayed by gas chromatography-mass spectrometry with use of a capillary column coated with chiral stationary phase that enabled baseline resolution of the four stereoisomers, designated hereafter as A, B, C, and D (where A and C, together with B and D, represent enantiomeric pairs). Results: In healthy subjects, stereoisomers A, C, and D showed similar kinetics, with an apparent oral clearance (CL/F) of about 4 1/4 L/hr, a half-life (t( 1/4 )) of about 10 hours, and an apparent volume of distribution (V(SS)/F) of about 65 L. However, stereoisomer B showed a much higher clearance (8.7 ± 0.9 L/hr) and a shorter t( 1/4 ) (5.8 hours). For all stereoisomers, CL/F values in patients with epilepsy were about tenfold higher than those found in healthy subjects. Compared with healthy subjects, patients with epilepsy also showed shorter t( 1/4 ) values and higher V(SS)/F values for each of the stereoisomers. After 7-day dosing, CL/F values at steady state were lower than those determined in the same patients after a single dose. Conclusions: Valnoctamide exhibits enantioselectivity and diastereoselectivity, an observation that may have important practical implications if pharmacodynamic differences between stereoisomers are also found. The observed pharmacokinetic differences between healthy subjects and patients with epilepsy are likely to be related to induction of metabolism of valnoctamide stereoisomers by carbamazepine.",
author = "S. Barel and B. Yagen and V. Schurig and S. Soback and F. Pisani and E. Perucca and M. Bialer",
year = "1997",
language = "English",
volume = "61",
pages = "442--449",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy

AU - Barel, S.

AU - Yagen, B.

AU - Schurig, V.

AU - Soback, S.

AU - Pisani, F.

AU - Perucca, E.

AU - Bialer, M.

PY - 1997

Y1 - 1997

N2 - Objective: To investigate the pharmacokinetics of the four stereoisomers of valnoctamide, a mild tranquilizer endowed with anticonvulsant properties. Methods: Racemic valnoctamide, 400 mg, was administered orally to seven healthy subjects and to six patients with epilepsy stabilized with long-term carbamazepine therapy. In the patients with epilepsy, valnoctamide kinetics was also reassessed after 8-day oral dosing at a dosage of 600 mg daily. Plasma samples were assayed by gas chromatography-mass spectrometry with use of a capillary column coated with chiral stationary phase that enabled baseline resolution of the four stereoisomers, designated hereafter as A, B, C, and D (where A and C, together with B and D, represent enantiomeric pairs). Results: In healthy subjects, stereoisomers A, C, and D showed similar kinetics, with an apparent oral clearance (CL/F) of about 4 1/4 L/hr, a half-life (t( 1/4 )) of about 10 hours, and an apparent volume of distribution (V(SS)/F) of about 65 L. However, stereoisomer B showed a much higher clearance (8.7 ± 0.9 L/hr) and a shorter t( 1/4 ) (5.8 hours). For all stereoisomers, CL/F values in patients with epilepsy were about tenfold higher than those found in healthy subjects. Compared with healthy subjects, patients with epilepsy also showed shorter t( 1/4 ) values and higher V(SS)/F values for each of the stereoisomers. After 7-day dosing, CL/F values at steady state were lower than those determined in the same patients after a single dose. Conclusions: Valnoctamide exhibits enantioselectivity and diastereoselectivity, an observation that may have important practical implications if pharmacodynamic differences between stereoisomers are also found. The observed pharmacokinetic differences between healthy subjects and patients with epilepsy are likely to be related to induction of metabolism of valnoctamide stereoisomers by carbamazepine.

AB - Objective: To investigate the pharmacokinetics of the four stereoisomers of valnoctamide, a mild tranquilizer endowed with anticonvulsant properties. Methods: Racemic valnoctamide, 400 mg, was administered orally to seven healthy subjects and to six patients with epilepsy stabilized with long-term carbamazepine therapy. In the patients with epilepsy, valnoctamide kinetics was also reassessed after 8-day oral dosing at a dosage of 600 mg daily. Plasma samples were assayed by gas chromatography-mass spectrometry with use of a capillary column coated with chiral stationary phase that enabled baseline resolution of the four stereoisomers, designated hereafter as A, B, C, and D (where A and C, together with B and D, represent enantiomeric pairs). Results: In healthy subjects, stereoisomers A, C, and D showed similar kinetics, with an apparent oral clearance (CL/F) of about 4 1/4 L/hr, a half-life (t( 1/4 )) of about 10 hours, and an apparent volume of distribution (V(SS)/F) of about 65 L. However, stereoisomer B showed a much higher clearance (8.7 ± 0.9 L/hr) and a shorter t( 1/4 ) (5.8 hours). For all stereoisomers, CL/F values in patients with epilepsy were about tenfold higher than those found in healthy subjects. Compared with healthy subjects, patients with epilepsy also showed shorter t( 1/4 ) values and higher V(SS)/F values for each of the stereoisomers. After 7-day dosing, CL/F values at steady state were lower than those determined in the same patients after a single dose. Conclusions: Valnoctamide exhibits enantioselectivity and diastereoselectivity, an observation that may have important practical implications if pharmacodynamic differences between stereoisomers are also found. The observed pharmacokinetic differences between healthy subjects and patients with epilepsy are likely to be related to induction of metabolism of valnoctamide stereoisomers by carbamazepine.

UR - http://www.scopus.com/inward/record.url?scp=0030907689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030907689&partnerID=8YFLogxK

M3 - Article

C2 - 9129561

AN - SCOPUS:0030907689

VL - 61

SP - 442

EP - 449

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -